(Q40647611)

22 September 2017

1 reference

title

Population and Bayesian pharmacokinetics in oncology (English)

1 reference

22 September 2017

Ranson MR

1

1 reference

PubMed ID

7986764

22 September 2017

Scarffe JH

series ordinal

2

1 reference

22 September 2017

1 January 1994

1 reference

22 September 2017

1 reference

22 September 2017

6

1 reference

22 September 2017

254-260

1 reference

22 September 2017

4

1 reference

Is dose normalization to weight or body surface area useful in adults?

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

An Improved Method of Digoxin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Individualization of phenytoin dosage regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Serum-phenytoin levels in management of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Intravenous theophylline therapy: nomogram guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Gentamicin serum concentrations: pharmacokinetic predictions

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Modelling of individual pharmacokinetics for computer-aided drug dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Forecasting individual pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetic and pharmacodynamic data and models in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Anticancer drug pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Population Pharmacokinetics/Dynamics*

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Bayesian parameter estimation and population pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Modeling interpatient pharmacodynamic variability of etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Approaches to optimal dosing of hexamethylene bisacetamide

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Adaptive control with feedback strategies for suramin dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

A limited sampling method for estimation of the carboplatin area under the curve.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Clinical utility of a Bayesian dosing program for phenytoin.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

Bayesian forecasting of serum lithium concentrations. Comparison with traditional methods

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

The accuracy and stability of Bayesian theophylline predictions.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980297-3

7 January 2021

10.1016/S0936-6555(05)80297-3

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

7986764